Ultragenyx Pharmaceutical Inc to Post FY2019 Earnings of ($6.79) Per Share, Piper Jaffray Companies Forecasts (RARE)
Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) – Analysts at Piper Jaffray Companies lifted their FY2019 earnings per share (EPS) estimates for shares of Ultragenyx Pharmaceutical in a research report issued to clients and investors on Wednesday, August 29th. Piper Jaffray Companies analyst C. Raymond now anticipates that the biopharmaceutical company will post earnings of ($6.79) per share for the year, up from their prior forecast of ($6.80). Piper Jaffray Companies currently has a “Overweight” rating and a $85.00 target price on the stock. Piper Jaffray Companies also issued estimates for Ultragenyx Pharmaceutical’s Q4 2019 earnings at ($1.71) EPS, FY2020 earnings at ($5.63) EPS, FY2021 earnings at ($2.96) EPS and FY2022 earnings at $1.59 EPS.
Other equities research analysts have also issued reports about the stock. Canaccord Genuity boosted their price objective on shares of Ultragenyx Pharmaceutical from $80.00 to $90.00 and gave the company a “buy” rating in a report on Friday, August 3rd. Robert W. Baird restated a “buy” rating and set a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, August 3rd. BidaskClub downgraded shares of Ultragenyx Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 25th. ValuEngine upgraded shares of Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, May 26th. Finally, JPMorgan Chase & Co. restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday. Four research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $80.53.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.08) by $1.02. The firm had revenue of $12.79 million for the quarter, compared to analyst estimates of $5.63 million. Ultragenyx Pharmaceutical had a negative net margin of 703.27% and a negative return on equity of 44.09%. During the same period in the previous year, the company earned ($1.72) earnings per share.
In other Ultragenyx Pharmaceutical news, CFO Shalini Sharp sold 6,700 shares of the company’s stock in a transaction dated Thursday, June 7th. The shares were sold at an average price of $80.07, for a total value of $536,469.00. Following the completion of the transaction, the chief financial officer now owns 60,178 shares in the company, valued at $4,818,452.46. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Karah Herdman Parschauer sold 5,000 shares of the company’s stock in a transaction dated Tuesday, August 21st. The stock was sold at an average price of $78.53, for a total transaction of $392,650.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 18,969 shares of company stock valued at $1,500,989. Insiders own 8.40% of the company’s stock.
Several institutional investors have recently modified their holdings of the business. Covington Capital Management acquired a new position in shares of Ultragenyx Pharmaceutical during the 1st quarter worth about $102,000. Rockefeller Capital Management L.P. acquired a new position in shares of Ultragenyx Pharmaceutical during the 1st quarter worth about $108,000. Advisors Asset Management Inc. acquired a new position in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth about $181,000. Hsbc Holdings PLC acquired a new position in shares of Ultragenyx Pharmaceutical during the 1st quarter worth about $213,000. Finally, Silvant Capital Management LLC acquired a new position in shares of Ultragenyx Pharmaceutical during the 1st quarter worth about $233,000. Institutional investors and hedge funds own 96.25% of the company’s stock.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.
Featured Story: Understanding Price to Earnings Ratio (PE)
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.